Rasmus Just
Director/Board Member at Vjack Holding Ivs
Network origin in Rasmus Just first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 42 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Rasmus Just via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| University of Copenhagen | College/University | Corporate Officer/Principal Doctorate Degree Doctorate Degree Undergraduate Degree Doctorate Degree Graduate Degree Doctorate Degree Graduate Degree | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Copenhagen Business School | College/University | Undergraduate Degree Graduate Degree Graduate Degree Graduate Degree | |
| University of Lund | College/University | Graduate Degree Doctorate Degree Graduate Degree Undergraduate Degree | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Chief Executive Officer Chairman Director/Board Member Founder | |
| University of Aarhus | College/University | Corporate Officer/Principal Graduate Degree Masters Business Admin Undergraduate Degree | |
| ATON | Pharmaceuticals: Major | Director/Board Member Chairman Chairman | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer Director/Board Member | |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Generic | Director/Board Member Director/Board Member Director/Board Member | |
| VALERIO THERAPEUTICS | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| International Institute for Management Development | College/University | Masters Business Admin Undergraduate Degree Masters Business Admin | |
Roche Innovation Center Copenhagen A/S
 Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chairman Director/Board Member Chairman | |
| University of Oxford | College/University | Undergraduate Degree Undergraduate Degree | |
| SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Chief Executive Officer Chief Operating Officer | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Danmarks Farmaceutiske Universitet | College/University | Graduate Degree Graduate Degree | |
Kymab Group Ltd.
 Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Part of Sanofi, Kymab Group Ltd. is a British biopharmaceutical company that develops human monoclonal antibody drugs. The company is based in Cambridge, UK. The company was founded in 2016 by Alan Bradley. Kymab Group was acquired by Sanofi Foreign Participations BV on April 09, 2021 for $1,970.99 million. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Step Pharma SAS
 Step Pharma SAS Pharmaceuticals: MajorHealth Technology Step Pharma SAS develops drugs for immunosuppressive therapies. The company was founded by Geoffroy de Ribains, Alain Fischer, and Sylvain Latour and is headquartered in Paris, France. | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
| ADOCIA | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Key Neurosciences SAS
 Key Neurosciences SAS Miscellaneous Commercial ServicesCommercial Services Key Neurosciences SAS provides research and development services. Its services include product and technology development, fund raising, business and commercial development, and project management. The company was founded in December 2010 and is headquartered in Paris, France. | Miscellaneous Commercial Services | Director/Board Member Chairman | |
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Biotechnology | Director/Board Member Director/Board Member | |
| CELLECTIS S.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Zymenex A/S
 Zymenex A/S BiotechnologyHealth Technology Zymenex A/S researches and develops therapeutics for life threatening diseases. The firm commercializes novel enzyme replacement therapies for the treatment of life-threatening, rare genetic diseases. The company was founded by Jens Fogh and Pär Gellerfors in 1998 and is headquartered in Hillerod, Denmark. | Biotechnology | Chairman Chairman | |
Opsona Therapeutics Ltd.
 Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| VALNEVA | Biotechnology | Corporate Officer/Principal Director/Board Member | |
| EGETIS THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Chairman | |
Auris Medical AG
 Auris Medical AG Medical SpecialtiesHealth Technology Auris Medical AG manufactures electronic devices for ear disorders. It develops novel pharmaceutical therapies to protect hearing and to silence tinnitus. The company was founded by Thomas Meyer in April 2003 and is headquartered in Basel, Switzerland. | Medical Specialties | Director/Board Member Director/Board Member | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Chief Tech/Sci/R&D Officer Director/Board Member | |
| ALTAMIRA THERAPEUTICS LTD. | Biotechnology | Director/Board Member Director/Board Member | |
| TDC A/S | Major Telecommunications | Corporate Officer/Principal Corporate Officer/Principal | |
Warren Pharmaceuticals, Inc.
 Warren Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Warren Pharmaceuticals, Inc. develops tissue-protective technologies. The company was founded by Anthony Cerami and Michael Brines on May 17, 2001 and is headquartered in Tarrytown, NY. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| CESSATECH A/S | Pharmaceuticals: Major | Director/Board Member Chief Operating Officer | |
Dansk Biotek
 Dansk Biotek Miscellaneous Commercial ServicesCommercial Services Dansk Biotek is an industry association for biotech companies with promoting the biotechnological research, development and production in taking care of corporate interests in this regard, both nationally and internationally. The company was founded in 1987 and is headquartered in Copenhagen, Denmark. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree | |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal | |
| AMRYT PHARMA PLC | Pharmaceuticals: Major | Director/Board Member | |
| DBV TECHNOLOGIES | Pharmaceuticals: Major | Director of Finance/CFO |
Statistics
International
| Denmark | 18 |
| France | 12 |
| United Kingdom | 8 |
| Sweden | 6 |
| Switzerland | 5 |
Sectoral
| Health Technology | 32 |
| Consumer Services | 9 |
| Commercial Services | 7 |
| Finance | 5 |
| Communications | 2 |
Operational
| Director/Board Member | 288 |
| Corporate Officer/Principal | 104 |
| Independent Dir/Board Member | 75 |
| Chairman | 70 |
| Chief Executive Officer | 52 |
Most connected contacts
| Insiders | |
|---|---|
| Peter James Arthur Benson | 58 |
| Alain Munoz | 38 |
| Christian Herskind Jørgensen | 35 |
| Alf Gunnar Martin Nicklasson | 31 |
| Rémi Droller | 29 |
| Catherine Moukheibir | 29 |
| Rosemary Crane | 23 |
| Jørgen Lindegaard | 22 |
| David Solomon | 22 |
| Jutta af Rosenborg | 21 |
| Michael Owen | 20 |
| Mats Blom | 15 |
| Britt Meelby Jensen | 15 |
| Bo Lennart Bruce | 15 |
| Florian Reinaud | 15 |
- Stock Market
- Insiders
- Rasmus Just
- Company connections
